NCT04075331View on ClinicalTrials.gov

Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

238

Participants

Timeline

Start Date

September 7, 2020

Primary Completion Date

June 21, 2024

Study Completion Date

June 21, 2024

Conditions
COPDEosinophilia
Interventions
DRUG

Mepolizumab

Mepolizumab 100mg subcutaneous injection

DRUG

Placebo

Saline solution for subcutaneous injection

Trial Locations (1)

LE1 9QP

NIHR Biomedical Research Centre, Respiratory, Leicester

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Leicester

OTHER